View the latest news and SEC filings
Scroll to
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45 th Annual Health Care Conference Date: Monday,
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a broad COPD population Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
March 18, 2025 |
An annual report to security holders |
ARS |
Annual Filings |
|
|
March 18, 2025 |
Official notification to shareholders of matters to be brought to a vote (“Proxy”) |
DEF 14A |
Proxy Filings |
|
|
March 13, 2025 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
March 12, 2025 |
Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing |
144 |
Other |
|
|
February 28, 2025 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
February 27, 2025 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
February 27, 2025 |
Annual report which provides a comprehensive overview of the company for the past year |
10-K |
Annual Filings |
|
|
February 27, 2025 |
Securities offered to employees pursuant to employee benefit plans |
S-8 |
Registration Statements |
|
|
February 14, 2025 |
SCHEDULE 13G/A – Description |
SCHEDULE 13G/A |
No terms found |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
